Which of the following antiarrhythmic drugs is contraindicated in a patient with interstitial lung disease?

Correct Answer: D. Amiodarone

Amiodarone is absolutely contraindicated in interstitial lung disease (ILD) because it causes pulmonary toxicity as one of its most serious adverse effects. Amiodarone accumulates in lung tissue due to its high lipophilicity and long half-life (40–50 days), leading to direct pneumonitis, pulmonary fibrosis, and exacerbation of pre-existing ILD. The incidence of amiodarone-induced pulmonary toxicity ranges from 1–17%, with higher risk in patients with baseline pulmonary disease. The mechanism involves phospholipidosis, oxidative stress, and inflammatory infiltration of alveolar tissue. In a patient with existing ILD, amiodarone would accelerate pulmonary deterioration, increase hypoxemia, and potentially lead to acute respiratory failure. Indian guidelines and clinical practice strongly recommend avoiding amiodarone in any patient with known or suspected ILD, COPD, or significant baseline pulmonary compromise. Alternative antiarrhythmics with safer pulmonary profiles should be selected instead.

Why the other options are wrong

A. Lignocaine — Lignocaine (lidocaine) is a Class IB antiarrhythmic with minimal pulmonary toxicity. It is metabolized hepatically and does not accumulate in lung tissue. It is safe in ILD patients and is often a preferred choice for acute arrhythmias in this population. NBE may include this as a distractor because it is also an antiarrhythmic, but it lacks amiodarone's pulmonary accumulation property. B. Sotalol — Sotalol is a Class III antiarrhythmic (beta-blocker with potassium-channel blocking properties) with no direct pulmonary toxicity. While beta-blockers can theoretically cause bronchospasm in asthmatic patients, sotalol does not cause the phospholipidosis or pulmonary fibrosis seen with amiodarone. It is relatively safe in ILD. NBE pairs it with amiodarone to test whether students confuse Class III drugs. C. Quinidine — Quinidine is a Class IA antiarrhythmic with rare, mild pulmonary side effects (mainly cinchonism). It does not cause the severe pulmonary fibrosis or pneumonitis characteristic of amiodarone. Although quinidine has fallen out of favor in modern Indian practice due to its proarrhythmic potential and GI side effects, it is not contraindicated in ILD. NBE uses it to distract from amiodarone's unique pulmonary toxicity profile.

High-Yield Facts

Mnemonics

AMIO-LUNG Accumulates in lung tissue → Massive phospholipidosis → Inflammation & fibrosis → Oxidative stress. Contraindicated in LUNG disease (ILD, COPD). Amiodarone Toxicity: SATIN Skin (blue-gray), Arrhythmia (proarrhythmic), Thyroid, Interstitial lung disease, Neurological. Use when recalling amiodarone's multi-organ toxicity profile.

NBE Trap

NBE pairs amiodarone with other Class III antiarrhythmics (like sotalol) to test whether students know that amiodarone's pulmonary toxicity is unique among antiarrhythmics, not a class effect. Students who confuse Class III properties with amiodarone-specific toxicity may incorrectly eliminate sotalol.

Clinical Pearl

In Indian tertiary care settings, amiodarone is often the first-line antiarrhythmic for refractory atrial fibrillation; however, any patient presenting with ILD (common in post-TB, silicosis, or occupational lung disease populations) must be screened for baseline pulmonary function before amiodarone initiation. A single dose of amiodarone in an ILD patient can precipitate acute decompensation.

_Reference: KD Tripathi Pharmacology Ch. 31 (Antiarrhythmics); Harrison Principles of Internal Medicine Ch. 227 (Arrhythmias)_